V-LAP

About This Project

Heart failure (HF) is a chronic condition, affecting 1 in 5 people aged over 65 worldwide, in which inefficient heart pumping causes body fluid retention and decreases a patient’s quality of life through dyspnea (shortness of breath), peripheral edema (leg swelling) and fatigue. The sudden worsening of symptoms, called Acute Decompensated Heart Failure (ADHF), is a life-threatening condition with 30% mortality within 12 weeks.

 

HF costs around €28B/year. There are 1 million new diagnoses of HF annually, and a 44% readmission rate within a year of the first acute event.  There is a need to increase awareness in HF, whose management is still highly ineffective. The transition from HF to ADHF takes weeks but a very early indicator exists, an increase in left ventricular filling pressure (LV). However this can only be measured invasively in a hospital. Current implantable monitoring methods have issues around efficacy, usability and portability.

 

Vectorious have developed V-LAP™, a sophisticated yet easy-to-use, scalable solution to measure LV pressure during daily life. V-LAP™ is composed of three elements: a miniaturized, battery-free pressure sensor implanted into the patient’s left heart chamber through a minimally invasive, catheter-based procedure: a wearable external device used for 1 minute per day to interrogate the implant; and a cloud platform that collects the patient’s hemodynamic data. If a rise in LV is detected, the clinician is alerted and the patient is contacted to change his drug therapy accordingly.

 

V-LAP™ will be able to predict at least 98% of ADHF events and reduce hospital readmission by at least 43%, saving around  €3.8B. The vision is to make HF management as simple and effective as managing glucose levels in diabetics.

Topic
ICT
Year

2017

Cutoff

February

Beneficiaries

Coordinator

Vectorious Medical Technologies Ltd.

Country

Israel